One biomarker identified to predict decreased benefit from the addition of rituximab to fludarabine and cyclophosphamide in CLL treatment is the presence of NOTCH1 mutation (Stilgenbauer et al., 2014). Here, NOTCH1 is linked to B-cell chronic lymphocytic leukemia.